Search company, investor...

Terranueva Pharma


Reverse Merger | IPO

About Terranueva Pharma

Terranueva Pharma is a technology-driven company that seeks to supply Canadian and international markets with premium quality medical cannabis for the relief of anxiety, chronic pain, migraines, and sleep disorders, and take advantage of new opportunities created by the legalization of recreational marijuana.

Headquarters Location

255, boul. Curé-Labelle Suite 204

Laval, Quebec, H7L 2Z9,


Missing: Terranueva Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Terranueva Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Terranueva Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Terranueva Pharma is included in 2 Expert Collections, including Cannabis.



3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.


Sleep Health & Wellness

804 items

These companies aim to assess or improve the quantity/quality of sleep, or use sleep data in the monitoring or diagnosis of other health conditions.

Latest Terranueva Pharma News

Terranueva Closes a Private Placement of Debentures for $2,950,000

Jul 13, 2022

Terranueva Closes a Private Placement of Debentures for $2,950,000 L’ASSOMPTION, Québec, July 13, 2022 (GLOBE NEWSWIRE) — Terranueva Corporation (CSE: TEQ) (“Terranueva” or the “Corporation”) announces the closing of a non-brokered private placement of second rank convertible debentures for an aggregate gross principal amount of $2,950,000 paid in cash and bearing an interest rate of 5% per annum (the “Offering”). The principal amount and interest are payable in five years, namely at the maturity of July 12, 2027, and the principal amount is convertible at any time until July 13, 2025, at the option of the holder, into voting common shares of the share capital of Terranueva (“Common Shares”) at a conversion price of $0.08 per Common Share. The debentures will be secured by a second rank hypothec on the universality of the Corporation’s movable property. The debentures and the underlying Common Shares are subject to a mandatory holding period of four months and one day from the closing. All parties to the Offering are dealing at arm’s length with Terranueva, except the participation of an officer and controlling shareholder of the Corporation described below, and no commission was payable. The whole is subject to applicable regulatory approvals. The proceeds of the Offering will be used primarily to replenish the Corporation’s working capital and for business development. An officer and controlling shareholder of the Corporation subscribed, directly and indirectly, for an aggregate principal amount of $2,315,750 convertible into up to a potential of 28,946,875 Common Shares. Its current holding on a non-diluted basis remains unchanged at 26.92% while its holding on a partially diluted basis (should a potential conversion occurs), currently of 42.47% will increase by 13.95% following the conversion of the total gross principal amount of the Offering. The issuance of the debentures to this insider constitutes a related party transaction, but which is exempt from the requirement to provide a formal valuation and obtain minority approval under Regulation 61-101 respecting Protection of Minority Security Holders in Special Transactions, and the board of directors of the Corporation, which includes independent directors in respect of the transaction who are not employees of the Corporation, has unanimously approved the Offering. In addition, neither the Corporation nor the said related party has knowledge of any material information concerning the Corporation or its securities that has not been generally disclosed. Terranueva did not file a material change report with respect to the insider’s interest at least 21 days prior to the date of the closing of the private placement, as such insider’s interest was not determined at that time. ABOUT TERRANUEVA Terranueva relies on research and development, innovation and operational efficiency to become a major player in the emerging cannabis industry. Their goal is to provide the Canadian and international markets with premium quality cannabis. To achieve this goal, Terranueva is implementing a modular production approach that incorporates the latest advances and innovations in process automation. Terranueva Pharma Corporation, its wholly owned subsidiary, holds the necessary licenses from Health Canada to execute its mission. For more on Terranueva, visit The CSE and its regulatory service providers (as this term is attributed in its policies) assume no responsibility for the relevance or accuracy of this press release.

Terranueva Pharma Frequently Asked Questions (FAQ)

  • Where is Terranueva Pharma's headquarters?

    Terranueva Pharma's headquarters is located at 255, boul. Curé-Labelle, Laval.

  • What is Terranueva Pharma's latest funding round?

    Terranueva Pharma's latest funding round is Reverse Merger.

  • Who are the investors of Terranueva Pharma?

    Investors of Terranueva Pharma include AXE Exploration.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.